BRPI0507463A - uso de glufosfamide e gemcitabine , produto, e, combinação de glufosfamide e gemcitabine - Google Patents

uso de glufosfamide e gemcitabine , produto, e, combinação de glufosfamide e gemcitabine

Info

Publication number
BRPI0507463A
BRPI0507463A BRPI0507463-0A BRPI0507463A BRPI0507463A BR PI0507463 A BRPI0507463 A BR PI0507463A BR PI0507463 A BRPI0507463 A BR PI0507463A BR PI0507463 A BRPI0507463 A BR PI0507463A
Authority
BR
Brazil
Prior art keywords
glufosfamide
gemcitabine
combination
product
methods
Prior art date
Application number
BRPI0507463-0A
Other languages
English (en)
Inventor
George Tidmarsh
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of BRPI0507463A publication Critical patent/BRPI0507463A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE GLUFOSFAMIDE E GEMCITABINE, PRODUTO, E, COMBINAçãO DE GLUFOSFAMIDE E GEMCITABINE São descritos métodos para o tratamento de câncer. Em particular, são expostos métodos para o tratamento de câncer que compreedem a administração de glufosfamide isoladamente ou em combinação com um outro agente anti-cãncer.
BRPI0507463-0A 2004-02-06 2005-02-04 uso de glufosfamide e gemcitabine , produto, e, combinação de glufosfamide e gemcitabine BRPI0507463A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54249404P 2004-02-06 2004-02-06
PCT/US2005/003370 WO2005076888A2 (en) 2004-02-06 2005-02-04 Anti-cancer therapies

Publications (1)

Publication Number Publication Date
BRPI0507463A true BRPI0507463A (pt) 2007-07-10

Family

ID=34860311

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507463-0A BRPI0507463A (pt) 2004-02-06 2005-02-04 uso de glufosfamide e gemcitabine , produto, e, combinação de glufosfamide e gemcitabine

Country Status (16)

Country Link
US (3) US8318683B2 (pt)
EP (1) EP1711188B1 (pt)
JP (4) JP5235304B2 (pt)
KR (2) KR101226631B1 (pt)
CN (1) CN1917885A (pt)
AU (1) AU2005213372B2 (pt)
BR (1) BRPI0507463A (pt)
CA (1) CA2554463C (pt)
DK (1) DK1711188T3 (pt)
ES (1) ES2389809T3 (pt)
IL (1) IL177136A (pt)
NO (1) NO336884B1 (pt)
NZ (1) NZ549605A (pt)
RU (1) RU2006132069A (pt)
WO (1) WO2005076888A2 (pt)
ZA (1) ZA200606456B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
KR101226631B1 (ko) 2004-02-06 2013-01-28 쓰레솔드 파마슈티컬스, 인코포레이티드 항암 치료 방법
US20110182909A1 (en) * 2004-12-23 2011-07-28 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
JP5547487B2 (ja) * 2006-11-03 2014-07-16 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗癌化合物の投与方法
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
WO2008124691A1 (en) 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
WO2010019396A1 (en) * 2008-08-13 2010-02-18 Threshold Pharmaceuticals, Inc. Administration of glufosfamide for the treatment of cancer
TWI448295B (zh) 2011-11-15 2014-08-11 Univ Kaohsiung Medical 抗人類泌尿上皮癌之香桂超臨界萃取物、製備方法及用途
US11479878B2 (en) 2016-03-16 2022-10-25 Dana-Farber Cancer Institute, Inc. Methods for genome characterization
CN110248664B (zh) * 2017-11-28 2023-03-03 深圳艾欣达伟医药科技有限公司 葡磷酰胺的抗癌医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489302A (en) * 1979-09-24 1984-12-18 Eventoff Franklin Neal Electronic pressure sensitive force transducer
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
DE3835772A1 (de) * 1988-10-20 1990-04-26 Deutsches Krebsforsch Tumorhemmende saccharid-konjugate
DE19524515A1 (de) * 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US7452538B2 (en) * 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7001888B2 (en) * 2002-03-29 2006-02-21 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
MXPA05007382A (es) * 2003-01-10 2005-11-23 Threshold Pharmaceuticals Inc Tratamiento de cancer con 2-desoxiglucosa.
EP1601795A4 (en) 2003-03-07 2008-03-26 Threshold Pharmaceuticals Inc METHOD FOR DETERMINING THE SENSITIVITY OF A TUMOR AGAINST TREATMENT WITH AN ANTI-TUMBER AGENT
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
KR101226631B1 (ko) * 2004-02-06 2013-01-28 쓰레솔드 파마슈티컬스, 인코포레이티드 항암 치료 방법
US20110182909A1 (en) 2004-12-23 2011-07-28 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
JP2008540559A (ja) 2005-05-11 2008-11-20 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド グルフォスファミド併用療法
JP2009509974A (ja) 2005-09-23 2009-03-12 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 抗癌治療

Also Published As

Publication number Publication date
EP1711188A2 (en) 2006-10-18
ZA200606456B (en) 2008-01-08
KR20060131869A (ko) 2006-12-20
RU2006132069A (ru) 2008-03-20
NO20063987L (no) 2006-09-06
JP5235304B2 (ja) 2013-07-10
IL177136A (en) 2010-11-30
WO2005076888A3 (en) 2005-10-27
JP2017071625A (ja) 2017-04-13
DK1711188T3 (da) 2012-09-10
WO2005076888A2 (en) 2005-08-25
CA2554463A1 (en) 2005-08-25
CA2554463C (en) 2013-06-11
US20170157161A1 (en) 2017-06-08
JP2018177808A (ja) 2018-11-15
US8318683B2 (en) 2012-11-27
US20130045944A1 (en) 2013-02-21
EP1711188B1 (en) 2012-06-06
NO336884B1 (no) 2015-11-23
JP2013064002A (ja) 2013-04-11
CN1917885A (zh) 2007-02-21
KR20120117943A (ko) 2012-10-24
US9205098B2 (en) 2015-12-08
NZ549605A (en) 2010-01-29
AU2005213372A1 (en) 2005-08-25
IL177136A0 (en) 2006-12-10
JP2007520562A (ja) 2007-07-26
AU2005213372B2 (en) 2011-03-24
KR101226631B1 (ko) 2013-01-28
US20090247480A1 (en) 2009-10-01
ES2389809T3 (es) 2012-10-31

Similar Documents

Publication Publication Date Title
CL2008002381A1 (es) Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer.
CY2017029I1 (el) ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ
BRPI0606891A2 (pt) anticorpos dr5 e usos dos mesmos
CR11486A (es) Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
DK1866324T3 (da) Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
MX2008000915A (es) Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos.
BR112012011485A2 (pt) "composições e métodos para tratar náusea e vômito centralmente mediados".
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
UA85574C2 (uk) Ендопаразитоцидний засіб для місцевого застосування
CL2008003309A1 (es) Compuestos derivados de citosina (=4-amino-pirimidin-2-ona) sustituida, moduladores de quinasas de punto de control del ciclo celular; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento o la disminucion de la progresion del cancer.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
NO20072839L (no) 4-hydroksybenzomorfaner
PA8631801A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
CL2007003718A1 (es) Compuestos macrociclos, inhibidores selectivos del factor viia de coagulacion de serinaproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de un trastorno tromboembolico.
CL2008001323A1 (es) Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BRPI0507463A (pt) uso de glufosfamide e gemcitabine , produto, e, combinação de glufosfamide e gemcitabine
BRPI0509927A (pt) composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina
CL2009000665A1 (es) Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas.
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
BRPI0506888A (pt) composições de suplemento lìquido compreendendo um ou mais medicamentos
MX2009001433A (es) Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]